Detecting morphologically distinct oligomeric forms of alpha-synuclein.
about
Protective effects and potential mechanisms of Pien Tze Huang on cerebral chronic ischemia and hypertensive strokeIntrabodies as neuroprotective therapeuticsCurcumin reduces alpha-synuclein induced cytotoxicity in Parkinson's disease cell model.Isolation and characterization of antibody fragments selective for specific protein morphologies from nanogram antigen samples.Human α4β2 nicotinic acetylcholine receptor as a novel target of oligomeric α-synuclein.Isolation and characterization of antibody fragments selective for toxic oligomeric tauEngineered antibody therapies coming of age for aging brainsCSF levels of oligomeric alpha-synuclein and beta-amyloid as biomarkers for neurodegenerative disease.Toxic Oligomeric Alpha-Synuclein Variants Present in Human Parkinson's Disease Brains Are Differentially Generated in Mammalian Cell ModelsTDP-43 protein variants as biomarkers in amyotrophic lateral sclerosis.A Rapid, Semi-Quantitative Assay to Screen for Modulators of Alpha-Synuclein Oligomerization Ex vivo.Oligomeric α-synuclein and β-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseasesα-Synuclein oligomers and clinical implications for Parkinson disease.Evidence for prion-like mechanisms in several neurodegenerative diseases: potential implications for immunotherapyTransglutaminase activation in neurodegenerative diseases.Developing intrabodies for the therapeutic suppression of neurodegenerative pathology.The SH-SY5Y cell line in Parkinson's disease research: a systematic review.Basic mechanisms of neurodegeneration: a critical update.Targeting intracellular and extracellular alpha-synuclein as a therapeutic strategy in Parkinson's disease and other synucleinopathies.Structural, morphological, and functional diversity of amyloid oligomers.Review: Spreading the word: precise animal models and validated methods are vital when evaluating prion-like behaviour of alpha-synuclein.Recombinant Antibody Fragments for Neurodegenerative Diseases.Fusion to a highly charged proteasomal retargeting sequence increases soluble cytoplasmic expression and efficacy of diverse anti-synuclein intrabodies.Adenosine A2A Receptors Modulate α-Synuclein Aggregation and Toxicity.Nanobodies raised against monomeric ɑ-synuclein inhibit fibril formation and destabilize toxic oligomeric species.α-synuclein conformational antibodies fused to penetratin are effective in models of Lewy body disease.The Aggregation of Huntingtin and α-Synuclein.Trimeric tau is toxic to human neuronal cells at low nanomolar concentrations.A sensitive phage-based capture ELISA for sub-femtomolar detection of protein variants directly from biological samples.Novel atomic force microscopy based biopanning for isolation of morphology specific reagents against TDP-43 variants in amyotrophic lateral sclerosis.APP/Aβ structural diversity and Alzheimer's disease pathogenesis.Investigation of the effects of carbon-based nanomaterials on A53T alpha-synuclein aggregation using a whole-cell recombinant biosensor.CNS disease-related protein variants as blood-based biomarkers in traumatic brain injuryAntibody Therapy in Neurodegenerative Disease
P2860
Q21203063-9697F643-9108-4AED-9E74-C5C433D74B80Q27003896-D62BE86A-FF36-4768-9EBD-977002C9C24AQ33569173-10C534FA-5EB2-4712-B2DA-1A50A13B482DQ34566355-47D06177-18B4-49DE-940C-E810D26CEE8FQ34598256-DF85BC35-F061-4B22-864E-76781E51F60DQ35137455-BAE773B6-A753-4491-9D40-20C5D56F1C0FQ35596571-B7D1D2B1-0391-4296-A159-23FEA08495A4Q35906655-16563801-125C-492D-ADEE-DF2E4A39EB5EQ36139079-C0F96952-8B65-4D7B-888E-105236AFC48AQ36260146-2286D9AA-D900-4832-BAB5-C236E121C1ADQ36475337-C9CE8342-D2F7-4FFB-BF8F-CE94D0D6A37AQ36479597-11225480-5919-46EA-8F2E-E71B3858751DQ36718306-B837DCD2-4803-418B-AD89-BB9CEC63CCACQ37280507-AF47B829-C0F3-4B97-BFF1-2057D23CDE11Q37352964-73FDAD59-94CD-439B-A5DC-8CDE926DAEAFQ37571975-E8132E0B-AB8F-4A23-B99A-29AB602031BDQ37602366-4E657B42-F437-4CF0-B679-7C2C5D49B28AQ37673274-05881124-7221-493E-8D1B-44C138E1F903Q38000327-0FA5EF9C-F283-4B78-B991-ACB67615D212Q38549882-16C9D4D0-7BC3-409B-A02F-5016CFA9665BQ38669105-33D51D29-E9D3-4B32-9884-D628BB759DFAQ38970823-08658C13-C1D2-483A-93AF-D822FA5838EBQ39289367-EECF256B-6EB8-49C8-8A2D-87E778454B3AQ40358428-4F980E15-4BEB-4672-9C87-8C505BD35F86Q40968608-5FADD674-7487-4F14-B751-BDF0708B7C2CQ41117719-40821076-124D-4237-968D-81E1DBA7456CQ41834257-0A49072B-2A32-4692-9AA2-2C276893B78DQ42042649-E533AB8F-C849-4EC6-95D8-8C78682BB1FFQ42190840-E5C2E9EA-210F-4A13-B99A-80CF1BB59646Q42557993-E59D5021-A25E-4A23-9F01-24E9C2AC9F89Q46320596-390E4165-5C44-4249-AE21-9BB0F3C2E805Q47142619-8B2F32A9-D3CF-400B-9C19-ACCA3C31C176Q57291663-7FBE02BB-49FF-47A3-8A49-AE5E456E6F51Q58266477-C6860866-6B5E-45A8-8BB2-945D44AB4E2C
P2860
Detecting morphologically distinct oligomeric forms of alpha-synuclein.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Detecting morphologically distinct oligomeric forms of alpha-synuclein.
@ast
Detecting morphologically distinct oligomeric forms of alpha-synuclein.
@en
type
label
Detecting morphologically distinct oligomeric forms of alpha-synuclein.
@ast
Detecting morphologically distinct oligomeric forms of alpha-synuclein.
@en
altLabel
Detecting Morphologically Distinct Oligomeric Forms of α-Synuclein
@en
prefLabel
Detecting morphologically distinct oligomeric forms of alpha-synuclein.
@ast
Detecting morphologically distinct oligomeric forms of alpha-synuclein.
@en
P2093
P2860
P356
P1476
Detecting morphologically distinct oligomeric forms of alpha-synuclein.
@en
P2093
Michael R Sierks
Philip Schulz
Sharareh Emadi
Srinath Kasturirangan
P2860
P304
11048-11058
P356
10.1074/JBC.M806559200
P407
P50
P577
2009-01-13T00:00:00Z